Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
HOLLISTON, Mass., Feb. 23, 2017 -- Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer and marketer of a broad range of solutions to advance life science, will announce results for its fourth quarter 2016 after market trading hours on Thursday, March 9, 2017. A conference call to discuss the company's fourth quarter 2016 financial results and its operations is scheduled for that same date at 4:30 PM ET. On that call, management may respond to questions from the audience and provide information on any of a number of topics related to the business, including operations, plans and outlook.
Participating in the call will be Jeffrey A. Duchemin, President and Chief Executive Officer; and Robert Gagnon, Chief Financial Officer of Harvard Bioscience. Investors can access the live conference call by dialing the following phone numbers: toll-free 1-800-708-4539, or international: 1-847-619-6396, and referencing the conference ID# 44422279.
The conference will be simultaneously webcast and can be accessed through the Harvard Bioscience website. To listen to the webcast, log on to the webcast at:
http://investor.harvardbioscience.com/
and click on the Earnings Call icon. Financial information presented on the call, including the earnings release, will also be available on the investor relations section of the website.
If you are unable to listen to the live conference call, the webcast will be available on the Company's website through March 16, 2017.
To add this meeting to your calendar visit: http://investor.harvardbioscience.com/ and click “remind me”.
About Harvard Bioscience
Harvard Bioscience is a global developer, manufacturer and marketer of a broad range of solutions to advance life science. Our products are sold to thousands of researchers in over 100 countries through our global sales organization, websites, catalogs, and through distributors including Thermo Fisher Scientific Inc., VWR, GE Healthcare, and other specialized distributors. We have sales and manufacturing operations in the United States, the United Kingdom, Germany, Sweden, Spain, France, Canada and China. For more information, please visit our website at www.harvardbioscience.com.
CONTACTS: Jeffrey A. Duchemin CEO and President Robert E. Gagnon CFO Corey Manchester Director, Finance and Investor Relations Tel: 508 893 8999
